Logo

GC Genome/Celemics: SARS-CoV-2 BTSeq Sequencing Service

Apr 08, 2020

Korean firms GC Genome and Celemics have launched a SARS-CoV-2 sequencing service. As part of the service, GC Genome will use Celemics' Barcode-Tagged Sequencing (BTSeq) technology, which can analyze sequence sizes of less than 1 kb to a maximum of 30 kb with an error rate of less than .001 percent per base pair, the companies said. This enables analysis of both PCR products and full SARS-CoV-2 genomes. Turnaround time is usually less than 10 days but can be minimized to one day, the companies said. The partners said that the service can reveal information on the epidemiology and pathogenesis of the virus and enable mutant surveillance.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.